This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Classification codes | C79 (KCD-8 / ICD-10) |
| Special Copayment Reduction | V193 · 5 years from the cancer patient registration date · 5% copayment |
| Synonyms | Metastatic cancer, secondary malignant neoplasm (bone, brain, adrenal, kidney, bladder, skin, lymph node), bone metastasis, brain metastasis, adrenal metastasis, Secondary bone/brain/adrenal/skin/lymph node metastasis |
| Adult onset | Very high (appears at the progression stage of the primary cancer, especially after age 40) |
Contents
| A. | Classification codes | B. | Synonyms |
| 1. | History | 2. | Causes |
| 3. | Genetics | 4. | General epidemiology |
| 5. | Pathophysiology | 6. | Symptoms |
| 7. | Signs | 8. | Screening |
| 9. | Diagnosis | 10. | Treatment |
| 11. | Prognosis | 12. | Prevention |
| 13. | References | ||
| Code | Name |
|---|---|
| C79 | Secondary malignant neoplasm of other and unspecified sites |
| C79.0 | Secondary malignant neoplasm of kidney and renal pelvis |
| C79.1 | Secondary malignant neoplasm of bladder and other urinary organs |
| C79.2 | Secondary malignant neoplasm of skin |
| C79.3 | Secondary malignant neoplasm of brain and cerebral meninges (C79.31 brain, C79.32 cerebral meninges) |
| C79.4 | Secondary malignant neoplasm of other and unspecified parts of nervous system |
| C79.5 | Secondary malignant neoplasm of bone and bone marrow (C79.51 bone, C79.52 bone marrow) |
| C79.6 | Secondary malignant neoplasm of ovary |
| C79.7 | Secondary malignant neoplasm of adrenal gland |
| C79.8 | Secondary malignant neoplasm of other specified sites |
| C79.9 | Secondary malignant neoplasm of unspecified site |
Metastatic cancer, bone metastasis, brain metastasis (cerebral metastasis), adrenal metastasis, leptomeningeal metastasis (leptomeningeal carcinomatosis), cutaneous metastasis, secondary malignant neoplasm. Bone metastases are classified as osteolytic or osteoblastic types, and brain metastases are classified as parenchymal and leptomeningeal. Adrenal metastasis is particularly frequent in lung cancer and is significant for lung cancer staging.
Bone metastasis has been recognized since ancient times. After Joseph Recamier established the concept of metastasis in 1829, pathologists in the late 19th century demonstrated by microscopic examination that bone lesions in breast, lung, and prostate cancer originate from a site different from the primary cancer. Pathological fracture and hypercalcemia of malignancy due to bone metastasis were recognized as clinically important complications in the early 20th century. The development of bisphosphonates—clodronate (1970s), pamidronate (1980s), zoledronic acid (2000s)—became established as a breakthrough treatment that significantly reduced skeletal-related events (SREs) in patients with bone metastasis.
Systematic study of brain metastasis advanced rapidly after the introduction of CT scanning in the mid-20th century. Brain metastases, which previously could be confirmed only at autopsy, became diagnosable during life with the spread of CT (1970s) and MRI (1980s). In the 1990s, whole-brain radiation therapy (WBRT) became established as the standard treatment for brain metastasis, but the adverse effect of neurocognitive decline was a problem. Since the 2000s, advances in stereotactic radiosurgery (SRS; Gamma Knife, CyberKnife) have made excellent local control possible without WBRT for limited brain metastases (oligometastasis). In the 2010s, improved blood–brain barrier penetration of EGFR tyrosine kinase inhibitors (osimertinib) and ALK inhibitors (alectinib) increased cases in which brain metastases are controlled by drug therapy alone.
The clinical importance of adrenal metastasis came to the fore as adrenal incidentalomas became commonly detected with the spread of CT. Because distinguishing whether an adrenal lesion in a lung cancer patient is a metastasis or a benign adenoma is decisive for staging, the roles of PET-CT and adrenal MRI are emphasized. Leptomeningeal metastasis was in the past difficult even to diagnose and had very limited treatment options, but diagnostic accuracy has improved with advances in cerebrospinal fluid cytology and cerebrospinal fluid ctDNA analysis, and intrathecal chemotherapy and epidural radiation therapy are being used in combination.
The discovery of the link between the RANK/RANKL axis and bone metastasis (late 1990s) led to the development of denosumab (an anti-RANKL monoclonal antibody), and large clinical trials comparing it with zoledronic acid (XGEVA trials) demonstrated superiority or non-inferiority in SRE prevention. In the 2020s, with radionuclide therapy—approval of radium-223 (Radium-223, Xofigo) for bone metastasis of prostate cancer (2013)—and the emergence of lutetium-177 PSMA (PSMA-RLT), new therapeutic horizons are opening in metastatic bone cancer as well.
Secondary malignant neoplasms of the C79 category result from cancer cells derived from a primary tumor settling in the site via hematogenous spread, lymphatic spread, or direct seeding. The preferred primary cancers differ by metastatic site.
Main primary cancers of bone metastasis: breast, prostate, lung, kidney, and thyroid cancers are the most common (remembered by the abbreviation BLT malignancies: Breast, Lung, Thyroid, Kidney, Prostate). These five cancers account for about 80% of bone metastases. Multiple myeloma is a hematologic cancer but causes extensive bone destruction, clinically resembling bone metastasis. Bone metastases of prostate cancer are mainly osteoblastic, while those of breast and lung cancer are osteolytic or mixed.
Main primary cancers of brain metastasis: in order, lung cancer (especially adenocarcinoma and small cell lung cancer), breast cancer, malignant melanoma, kidney cancer, and colorectal cancer. Lung cancer accounts for 40-50% of all brain metastases, and in small cell lung cancer brain metastasis develops in 50-80% within 2 years. Triple-negative breast cancer (TNBC) and HER2-positive breast cancer have a higher risk of brain metastasis than other breast cancer subtypes.
Main primary cancers of adrenal metastasis: lung cancer is the most common (incidence of adrenal metastasis in lung cancer 20-40%), followed by breast cancer, kidney cancer, and gastrointestinal cancers. The adrenal gland is known to be easily colonized by metastatic cancer cells because of its rich vascularity and high lipid content in the adrenal cortex.
Main primary cancers of leptomeningeal metastasis: incidence is high in breast cancer, lung cancer (adenocarcinoma), malignant melanoma, and hematologic tumors (ALL, NHL). In particular, cases in which leptomeningeal metastasis appears as a progression pattern after targeted therapy in patients with EGFR-mutant lung cancer are attracting clinical attention.
Genetics of bone metastasis: the CXCL12/CXCR4 axis mediates homing signals of cancer cells into the bone marrow. Interaction between RANK (receptor activator of NF-κB) and its ligand RANKL activates osteoclasts, causing osteolytic lesions. Parathyroid hormone-related protein (PTHrP) upregulates RANKL expression in breast cancer bone metastasis, promoting bone resorption. Osteoblastic metastasis of prostate cancer is associated with activation of the Wnt signaling pathway (especially Wnt3a, DKK1 inhibition).
Genetics of brain metastasis: to cross the blood–brain barrier (BBB), cancer cells express cyclooxygenase-2 (COX-2), matrix metalloproteinases (MMP-1, MMP-2), HB-EGF, and others. In lung cancer, EGFR exon 19 deletion/L858R mutation and ALK rearrangement increase the risk of brain metastasis, and at the same time third-generation TKIs targeting these alterations (osimertinib, alectinib) are highly effective against brain metastases. Molecular diagnosis in brain metastasis is also important for KRAS G12C mutation (targeted by sotorasib, adagrasib) and RET fusion (targeted by selpercatinib). HER2-amplified breast cancer has neurotropism and frequently causes brain metastasis, and the HER2-targeted ADC (trastuzumab deruxtecan, T-DXd) is effective in controlling brain metastases.
Genetics of adrenal metastasis: most metastatic tumors reach the adrenal gland hematogenously, and rich vascularity rather than a specific molecular mechanism is the important factor. However, in lung cancer, EGFR, ALK, KRAS mutation status affects the frequency and prognosis of adrenal metastasis.
Pharmacogenomics: in bone metastasis, the effect of denosumab (anti-RANKL) is associated with the activity of the RANK/RANKL pathway. In brain metastasis, molecular testing is essential for selecting targeted agents with high BBB penetration. PD-L1 expression, TMB (tumor mutational burden), and MSI-H status are used to predict response to immune checkpoint inhibitors. The effect of radium-223 is specific to osteoblastic bone metastasis (prostate cancer), and the level of PSMA expression is the criterion for selecting indications for lutetium-177 PSMA therapy.
Metastases in the C79 category are clinically common, and many cancer patients experience such metastases at diagnosis or during the course of the disease.
Bone metastasis (C79.5): bone metastasis develops in about 30-70% of all cancer patients, with particularly high incidence in breast cancer (65-75%), prostate cancer (65-75%), lung cancer (30-40%), and kidney cancer (20-25%). In Korea, the number of patients with bone metastasis is also trending upward with the increase in breast cancer (about 24,000 new diagnoses per year) and prostate cancer (about 17,000 per year). Bone metastasis causes serious skeletal-related events (SREs) such as pain, pathological fracture, spinal cord compression, and hypercalcemia, directly affecting quality of life and survival.
Brain metastasis (C79.3): brain metastasis develops in about 20-40% of all cancer patients, with lung and breast cancer as the main causes. Brain metastases are 10 times more common than primary brain tumors. In Korea, the incidence of lung cancer is high (about 30,000 per year), so the number of patients with brain metastasis is considerable. With improved MRI resolution, detection of small brain metastases that previously went undetected is increasing. With advances in targeted agents and immuno-oncology drugs, survival of patients with brain metastasis is trending longer, and control of brain metastases is becoming more important in the overall treatment strategy.
Adrenal metastasis (C79.7): adrenal metastasis develops in about 20-40% of lung cancer patients, and half of these already have adrenal metastasis at diagnosis. About 30-70% of adrenal incidentalomas are metastatic lesions (when there is a history of primary cancer). Differentiation of adrenal lesions found on CT is essential for staging and treatment planning in lung cancer.
Leptomeningeal metastasis (C79.32): occurs in about 5% of all patients with solid cancers and up to 15% in hematologic cancers. It is particularly frequent in breast cancer (3-5%), lung cancer (3-5%), and melanoma (5-20%). Median survival after diagnosis is only weeks to months, making it one of the metastasis types with the poorest prognosis.
Mechanism of bone metastasis (vicious cycle): after cancer cells settle in the bone marrow, they secrete PTHrP, IL-6, IL-11, IL-8, and others, activating osteoclasts. When osteoclasts break down bone, growth factors such as TGF-β and IGF-1 are released, further promoting cancer cell proliferation. This positive feedback loop (vicious cycle) accelerates the progression of osteolytic bone metastasis. In osteoblastic metastasis of prostate cancer, endothelin-1, BMP (bone morphogenetic protein), and Wnt signals secreted by cancer cells overactivate osteoblasts, causing abnormal new bone formation.
Mechanism of brain metastasis: the key barrier to the formation of brain metastasis is the blood-brain barrier (BBB). To cross the BBB, cancer cells express specific molecules: COX-2, HB-EGF, ST6GALNAC5 (involved in brain-selective metastasis of breast cancer), ANGPTL4 (disruption of lung capillaries). Within the brain, cancer cells engraft with the support of reactive astrocytes. Astrocytes help tumor survival and induce chemotherapy resistance through pyrimidine nucleoside phosphorylase (PLAUR). The blood-brain barrier limits the penetration of most anticancer drugs, making treatment of brain metastasis difficult. However, the BBB is partially disrupted at sites of brain metastasis (blood-brain tumor barrier, BBTB), allowing some passage of macromolecular drugs.
Mechanism of adrenal metastasis: the adrenal gland readily captures hematogenously metastasizing cancer cells through its abundant blood flow (0.5% of cardiac output) and extensive sinusoids. Adrenocortical steroids and epinephrine may act as immunosuppressive and growth factors that promote proliferation of metastatic cancer cells.
Mechanism of cutaneous metastasis (C79.2): cutaneous metastasis occurs in about 5-10% of cancer patients. It arises mainly from hematogenous spread, and breast cancer, melanoma, colorectal cancer, lung cancer, and gastric cancer are the main primary cancers. Umbilical metastasis (Sister Mary Joseph nodule) is a characteristic skin sign that appears from direct seeding of an intra-abdominal malignancy.
Symptoms of bone metastasis: bone metastasis pain is characterized by persistent, progressively worsening deep aching pain, especially severe at night. Pathological fracture pain that worsens with activity (especially spine, femoral neck). With spinal metastasis, radiating pain due to nerve root compression (radiculopathy). Malignant spinal cord compression (MSCC): lower limb weakness, sensory disturbance, bladder/bowel dysfunction—an oncologic emergency. Hypercalcemia: polyuria, polydipsia, nausea, constipation, stupor (hypercalcemia of malignancy is a common metabolic emergency).
Symptoms of brain metastasis: headache (worse in the morning, with nausea and vomiting, classic raised intracranial pressure headache), focal neurological deficits (hemiparesis, speech disturbance, visual field defects), cognitive dysfunction, personality change, seizures, gait ataxia. Cerebellar metastasis: gait ataxia and dizziness are the main symptoms. Brainstem metastasis: cranial nerve palsy symptoms such as diplopia, dysphagia, and facial palsy.
Symptoms of leptomeningeal metastasis: headache, nausea and vomiting (meningeal irritation), various cranial nerve palsies (diplopia, facial sensory disturbance, hearing loss), back and low back pain, bladder/bowel dysfunction, altered mental status. Because the symptoms are multifocal and nonspecific, diagnosis may be delayed.
Symptoms of adrenal metastasis: mostly asymptomatic and found incidentally on imaging. With extensive adrenal metastasis, adrenal insufficiency (Addison's disease-like symptoms: fatigue, anorexia, hypotension, hyponatremia, hyperkalemia) may appear. When adrenal insufficiency develops, steroid replacement is needed.
Signs of bone metastasis: tenderness is elicited on percussion or pressure over the metastatic site (tapping the spinous processes). With pathological fracture, deformity and swelling at the fracture site. With spinal cord compression, a sensory level below the lesion, hyperactive deep tendon reflexes, positive Babinski sign. Decreased consciousness and stupor due to hypercalcemia.
Signs of brain metastasis: papilledema due to raised intracranial pressure (confirmed on fundoscopy). Hemiparesis, hemianopia, and aphasia according to focal neurological deficits. Cerebellar signs (nystagmus, dysmetria, stuttering speech). Cushing's sign (hypertension, bradycardia, irregular respiration) indicates imminent brain herniation.
Key laboratory/imaging findings:
There is no general population screening for metastases in the C79 category. Targeted follow-up in patients with high-risk primary cancers is key.
Screening for bone metastasis: bone scan (bone scintigraphy) is used for staging and follow-up of breast, prostate, and lung cancer. In prostate cancer, a bone scan is recommended when PSA is elevated (>10 ng/mL) or Gleason score is ≥8. Specifically for prostate cancer, PSMA-PET/CT is more sensitive than conventional bone scan and is gradually replacing it as the standard test. Emergency screening for spinal cord compression: in patients with bone metastasis who newly develop lower limb weakness or voiding dysfunction, whole-spine MRI should be performed immediately.
Screening for brain metastasis: in small cell lung cancer, regular brain MRI follow-up is recommended even after prophylactic cranial irradiation (PCI). Regular brain MRI follow-up is considered in patients with EGFR-mutant/ALK-rearranged non-small cell lung cancer, HER2-positive and triple-negative breast cancer, and melanoma.
Screening for adrenal metastasis: in cancers at high risk of adrenal metastasis, such as lung and kidney cancer, regular abdominal CT including the adrenal glands is recommended. When an adrenal incidentaloma is found, metastasis is confirmed or excluded by PET-CT or adrenal MRI.
Diagnosis of bone metastasis:
Diagnosis of brain metastasis:
Differential diagnosis of adrenal metastasis:
Prevention of skeletal-related events (bone-protective agents): zoledronic acid (4 mg IV every 3-4 weeks, or every 12 weeks for maintenance) or denosumab (120 mg SC every 4 weeks) is the standard bone-protective treatment for patients with bone metastasis. Denosumab is superior to zoledronic acid in preventing SREs in breast cancer patients (XGEVA trial). Caution is needed with both agents for the adverse effect of osteonecrosis of the jaw (ONJ). Radium-223 (Xofigo): indicated for symptomatic bone metastases of metastatic castration-resistant prostate cancer. Selective treatment of bone metastatic sites with α radiation. Prolongs overall survival by about 3.6 months (ALSYMPCA trial).
Treatment of bone metastasis pain: analgesics according to the WHO three-step analgesic ladder (NSAIDs → weak opioids → strong opioids). External beam radiation therapy (EBRT): effective for pain of solitary metastasis (a single 8 Gy fraction is equally effective). Spinal cord compression: dexamethasone (immediately), radiation therapy (within 48 hours), or surgical decompression + posterior fixation.
Surgery: craniotomy for an accessible solitary large brain metastasis, when tissue confirmation is needed, or in emergencies with raised intracranial pressure. Stereotactic radiosurgery (SRS; Gamma Knife, CyberKnife): for 4 or fewer metastases with diameter of 3 cm or less, superior preservation of neurocognitive function compared with whole-brain radiation therapy (WBRT) alone. Whole-brain radiation therapy (WBRT): multiple (5 or more) brain metastases. Hippocampal-avoidance WBRT (HA-WBRT) partly reduces neurocognitive impairment. Targeted agents (good blood-brain barrier penetration): osimertinib (EGFR), alectinib and lorlatinib (ALK), capmatinib (METex14), trametinib and dabrafenib (BRAF V600E), larotrectinib (NTRK). T-DXd (brain metastasis of HER2 breast cancer). High-dose dexamethasone: immediate symptom relief of peritumoral cerebral edema.
A survival benefit of adrenalectomy for adrenal metastasis has been reported for solitary or few adrenal metastases when the primary cancer is well controlled. Laparoscopic adrenalectomy is considered first. Radiosurgery (SRS), radiofrequency ablation (RFA), and transarterial chemoembolization are also applied to unresectable adrenal metastases.
Intrathecal chemotherapy (intrathecal injection of methotrexate, cytarabine, thiotepa), radiation therapy to involved sites, systemic targeted agents (agents with high BBB penetration). Placement of an Ommaya reservoir facilitates repeated intrathecal administration.
| Type of metastasis | Median survival | Notes |
|---|---|---|
| Bone metastasis (breast cancer) | 24-36 months | Bone-protective agents + anticancer therapy |
| Bone metastasis (lung cancer) | 6-12 months | Varies greatly depending on control of the primary cancer |
| Brain metastasis (overall) | 4-12 months | Varies with primary cancer type and molecular subtype |
| Brain metastasis (EGFR lung cancer, osimertinib) | 20-30 months | Excellent response to targeted agents |
| Leptomeningeal metastasis | 2-6 months | Poorest prognosis |
| Adrenal metastasis (solitary, resected) | 24-36 months | Survival benefit with complete resection |
The Graded Prognostic Assessment (GPA) is used to predict the prognosis of brain metastasis. It stratifies prognostic groups by including primary cancer type, number of metastases, KPS (Karnofsky Performance Status), and control of the primary cancer. In bone metastasis, response to analgesics, occurrence of skeletal-related events, and ECOG performance status affect prognosis.
Early administration of bone-protective agents: in breast, prostate, and lung cancer, evidence is accumulating in some cancer types (especially lung cancer: studies of prophylactic zoledronic acid) that administration of bisphosphonates (zoledronic acid, clodronate) or denosumab at the adjuvant stage before bone metastasis develops delays or prevents bone metastasis.
Prevention of brain metastasis: prophylactic cranial irradiation (PCI) after complete remission of small cell lung cancer is standard. In EGFR/ALK-positive lung cancer, first-line use of BBB-penetrant targeted agents (osimertinib, alectinib) reduces the risk of developing brain metastasis. In HER2-positive breast cancer, optimization of HER2-targeted therapy (pertuzumab + trastuzumab maintenance) may lower the risk of brain metastasis.
Early treatment of the primary cancer: reducing systemic tumor burden through curative treatment of the primary cancer (surgery, adjuvant chemotherapy, radiation therapy) lowers the long-term risk of metastasis. Early detection of metastasis through regular follow-up can increase the opportunity for local treatment.